Jessica Chubak, PhD, is an epidemiologist who works to improve cancer diagnosis, treatment, control, and survivorship. She contributes to several national collaborations that are finding practical, efficient, effective ways to screen for cancer, especially colorectal cancer. She also studies how common medications affect cancer risk and recurrence. Intrigued by how pets positively affect health, Dr. Chubak is studying animal-assisted activities in clinics and hospitals where children get treated for cancer. Dr. Chubak’s methodological research focuses on the use of administrative and electronic health record data in epidemiologic and health services studies.
Dr. Chubak joined KPWHRI in 2007, bringing expertise in epidemiologic methods, pharmacoepidemiology, and cancer. Awarded a Fulbright graduate student grant, Dr. Chubak pursued her master's degree in bioethics and health law in New Zealand before completing her PhD in Epidemiology at the University of Washington (UW). Dr. Chubak is an affiliate associate professor in the Department of Epidemiology at the UW School of Public Health, where she enjoys guest-lecturing and getting to work with students.
Epidemiology; colorectal cancer; medication use; survivorship; recurrence; secondary prevention; quality of life; automated data collection; screening; animal-assisted activities; survivorship
Cancer risk and use of common medications
A'mar T, Beatty JD, Fedorenko C, Markowitz D, Corey T, Lange J, Schwartz SM, Huang B, Chubak J, Etzioni R. Incorporating breast cancer recurrence events into population-based cancer registries using medical claims: cohort study. JMIR Cancer. 2020 Aug 17;6(2):e18143. doi: 10.2196/18143. PubMed
Ghai NR, Jensen CD, Merchant SA, Schottinger JE, Lee JK, Chubak J, Kamineni A, Halm EA, Skinner CS, Haas JS, Green BB, Cannizarro NT, Schneider JL, Corley DA. Primary care provider beliefs and recommendations about colorectal cancer screening in four healthcare systems. Cancer Prev Res (Phila). 2020 Jul 15:canprevres.0109.2020. doi: 10.1158/1940-6207.CAPR-20-0109. [Epub ahead of print]. PubMed
Chubak J, Anderson ML, Cook AJ, Murphy CC, Jackson ML, Green BB. Methodological considerations in calculating and analyzing proportion of time covered as a measure of longitudinal cancer screening adherence. Cancer Epidemiol Biomarkers Prev. 2020 May 28:cebp.0388.2020. doi: 10.1158/1055-9965.EPI-20-0388. [Epub ahead of print]. PubMed
Hua X, Newcomb PA, Chubak J, Malen RC, Ziebell R, Kamineni A, Zhu LC, Upton MP, Wurscher MA, Thomas SS, Newman H, Hardikar S, Burnett-Hartman AN. Associations between molecular characteristics of colorectal serrated polyps and subsequent advanced colorectal neoplasia. Cancer Causes Control. 2020 May 1. doi: 10.1007/s10552-020-01304-1. [Epub ahead of print]. PubMed
Reding KW, Aragaki AK, Cheng RK, Barac A, Wassertheil-Smoller S, Chubak J, Limacher MC, Hundley WG, D'Agostino R Jr, Vitolins MZ, Brasky TM, Habel LA, Chow EJ, Jackson RD, Chen C, Morgenroth A, Barrington WE, Banegas M, Barnhart M, Chlebowski RT. Cardiovascular outcomes in relation to antihypertensive medication use in women with and without cancer: results from the Women's Health Initiative. Oncologist. 2020 Apr 6. doi: 10.1634/theoncologist.2019-0977. [Epub ahead of print]. PubMed
Chen L, Chubak J, Yu O, Pocobelli G, Ziebell RA, Aiello Bowles EJ, Fujii MM, Sterrett AT, Boggs JM, Burnett-Hartman AN, Ritzwoller DP, Hubbard RA, Boudreau DM. Changes in use of opioid therapy after colon cancer diagnosis: a population-based study. Cancer Causes Control. 2019 Dec;30(12):1341-1350. doi: 10.1007/s10552-019-01236-5. Epub 2019 Oct 30. PubMed
Tong J, Huang J, Chubak J, Wang X, Moore JH, Hubbard RA, Chen Y. An augmented estimation procedure for EHR-based association studies accounting for differential misclassification. J Am Med Inform Assoc. 2019 Oct 16. pii: 5588595. doi: 10.1093/jamia/ocz180. [Epub ahead of print]. PubMed
There’s much confusion about the new disease, but numbers don’t lie. The challenge is finding the right ones.
Research informs care as Kaiser Permanente Washington, exceeding 80 percent screening rate, launches home-based 'FIT First' pilot.
Read about it in News and Events.
Drs. Kamineni and Chubak are among leaders of 2 new large PROSPR awards from NCI for cervical and colorectal cancer screening research.
Read it in News and Events.